Principal Investigator
Robert Kirsner
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20241214
Clinical Trial Summary
LEO Pharma is the sponsor of this study and Boehringer Ingelheim is managing the study on behalf of the sponsor/A multi-centre, randomised, placebo-controlled, doubleblind,
parallel-group trial to evaluate safety and efficacy of
spesolimab (BI 655130) in adult patients with ulcerative
pyoderma gangrenosum (PG) who require systemic therapy
Phase
TBD
Funding Agency/Sponsor
Industry
Disease
Other